Gilead Sciences’ stock rose 8.30%
Gilead Sciences (GILD) is one of the top stocks in the iShares Nasdaq Biotechnology ETF (IBB). It has a weight of 7.03% of the entire portfolio. Gilead Sciences is also held by other ETFs like the Health Care Select Sector (XLV) and the First Trust Nyse Arca Biotech (FBT). It has a weight of 5.42% and 2.91%, respectively. For the week ending July 31, 2015, Gilead rose 8.13%.
Gilead announced its 2Q15 results on July 28, 2015. According to the company’s press release, it announced revenue of $8.2 billion—compared to $6.5 billion in 2Q14. It rose ~26%. On a sequential basis, the revenue rose ~8%. The report also stated that the company’s revenue from Europe rose by ~54% to $2 billion on a YoY (year-over-year) basis. Sequentially, it grew by 11.11%.
The net income was $4.5 billion for 2Q15—compared to $3.7 billion for 2Q14. The company also revised its full-year revenue guidance to $29–$30 billion.
The above chart shows the performance of Gilead compared to IBB on a month-over-month basis for 2015.
Gilead trades above the 100-day moving averages
Gilead closed at $119.53 as of July 31, 2015. It was trading above the 50, 20, and 100-day moving averages. Although the stock is trading close to the upper Bollinger price band, the 14-day RSI (relative strength index) is at 55. This indicates that the stock isn’t in overbought territory.